PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks